GoodRx (NASDAQ:GDRX) Sees Large Volume Increase - What's Next?

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) saw unusually-high trading volume on Monday . Approximately 1,694,854 shares were traded during mid-day trading, an increase of 18% from the previous session's volume of 1,433,816 shares.The stock last traded at $4.34 and had previously closed at $4.15.

Wall Street Analyst Weigh In

GDRX has been the topic of several recent analyst reports. Citigroup cut their target price on GoodRx from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, November 11th. UBS Group decreased their price objective on shares of GoodRx from $9.00 to $8.50 and set a "neutral" rating for the company in a report on Friday, August 9th. Raymond James raised shares of GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price for the company in a research report on Friday, August 9th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price objective on shares of GoodRx in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, GoodRx presently has a consensus rating of "Moderate Buy" and an average target price of $8.86.

GoodRx Price Performance

The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1.63 billion, a PE ratio of -142.33, a price-to-earnings-growth ratio of 3.02 and a beta of 1.39. The stock has a 50 day simple moving average of $6.48 and a 200-day simple moving average of $7.40.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.17% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cornercap Investment Counsel Inc. boosted its holdings in shares of GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company's stock valued at $587,000 after purchasing an additional 1,266 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of GoodRx by 5.1% in the 1st quarter. California State Teachers Retirement System now owns 70,912 shares of the company's stock valued at $503,000 after acquiring an additional 3,444 shares during the last quarter. US Bancorp DE lifted its holdings in shares of GoodRx by 3.7% in the 1st quarter. US Bancorp DE now owns 109,818 shares of the company's stock valued at $780,000 after acquiring an additional 3,877 shares during the last quarter. Beacon Capital Management LLC bought a new position in shares of GoodRx in the 1st quarter valued at about $28,000. Finally, nVerses Capital LLC bought a new position in shares of GoodRx in the 3rd quarter valued at about $33,000. Institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.